Oppenheimer Reiterates Perform Rating on Marinus Pharmaceuticals (MRNS)

Oppenheimer analyst Jay Olson reiterated a Perform rating and $9.00 price target on Marinus Pharmaceuticals (NASDAQ: MRNS).

The analyst commented, "We view OVID's Inter Partes Review (IPR) challenge of MRNS' patent No. 11,110,100 ('100 patent), related to methods for administering IV GNX in RSE, as likely futile, which appears consistent with consensus expectations based on today's share price reaction (MRNS +1% vs. NBI +2%). MRNS outlined its defense stating that the '100 patent covers clinical dosing regimens for RSE elucidated by its own Ph2 study that demonstrated rapid cessation of seizure burden with key PK insights, informing the dosing regimen for ongoing Ph3 RAISE trial. Additionally, we suspect PTAB may invalidate the remaining claims of OVID's patent No. 11,395,817 ('817 patent) in a ruling expected mid-2024. We believe MRNS' overall IP protection remains well-positioned, and look forward to Ph3 RAISE topline results expected in April/early-May."

For an analyst ratings summary and ratings history on Marinus Pharmaceuticals click here. For more ratings news on Marinus Pharmaceuticals click here.

Shares of Marinus Pharmaceuticals closed at $8.85 yesterday.

You May Also Be Interested In

• Golar LNG Ltd. (GLNG) PT Raised to $70 at BTIG
• Jumia Technologies (JMIA) PT Lowered to $11 at Cantor Fitzgerald
• Birkenstock Holding plc (BIRK) PT Raised to $44 at Morgan Stanley